Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Free Report) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 6,500 shares, a decline of 39.8% from the October 31st total of 10,800 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 8,900 shares, the short-interest ratio is currently 0.7 days.
Wall Street Analyst Weigh In
Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $8.00 price target on shares of Anebulo Pharmaceuticals in a research note on Tuesday, November 19th.
View Our Latest Research Report on ANEB
Anebulo Pharmaceuticals Stock Up 0.7 %
Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) last posted its earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. Research analysts expect that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.
Recommended Stories
- Five stocks we like better than Anebulo Pharmaceuticals
- Business Services Stocks Investing
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- What is a SEC Filing?
- MarketBeat Week in Review – 11/25 – 11/29
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.